UGT1A1 biomarker and colorectal cancer
What is the UGT1A1 biomarker?
The UGT1A1 gene is present in all the cells in our body. The normal UGT1A1 gene providesinstructions for making a certain enzyme called UDP glucuronosyltransferases, which helps the liver break down medications effectively.
What happens if I have the UGT1A1 biomarker?
If you have a mutation in the UGT1A1 gene, your body may not be able to process certain chemotherapy drugs.
Patients with this rare mutation have symptoms such as impaired liver function, low white cell counts, and severe diarrhea.
Your doctor will monitor you closely during your chemotherapy treatment to watch for any adverse reactions.
Who should have UGT1A1 testing?
UGT1A1 mutation testing is not routinely performed.
Patients are often tested if they have experienced severe toxicity during treatment with FOLFIRI, FOLFIRINOX, or irinotecan.
Other biomarkers
SidednessTop resources
Lexie Haglund: Beating stage IV CRC
Discover how knowing her G12C biomarker guided Lexie’s stage IV colorectal cancer treatment — from a shock diagnosis to HIPEC surgery — and why screening, research, and self-advocacy matter.
HAI liver pump for mCRC offers second chances
Discover how Hope overcame stage IV colorectal cancer with an innovative HAI liver pump, staying active and proving that second chances are possible.
Treatment for KRAS G12C-mutated metastatic CRC approved by FDA
The U.S. Food and Drug Administration has approved sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer.
